Search research articles
Contact Us
Filters
Showing results (311-320 of 315) with videos related to
Page
of 32
Sort By:
You have reached the last page of results.
This site can display upto 315 results.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
European Urology
|
December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
John L Gore, Erika M Wolff, Michael G Nash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2017
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
Veda N Giri, Karen E Knudsen, William K Kelly, et al.
Page
of 32
Search research articles
Search
Showing results (311-320 of 315) with videos related to
Sort By:
Page
of 32
You have reached the last page of results.
This site can display upto 315 results.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
European Urology
|
December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2025
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
John L Gore, Erika M Wolff, Michael G Nash, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2017
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
Veda N Giri, Karen E Knudsen, William K Kelly, et al.
Page
of 32